Emerging Company Profile

Exo: expanding the universe of druggable enzymes

Emerging Company Profile: David Liu’s latest newco launches with $25M to develop small molecules against non-catalytic, non-allosteric enzyme sites

David Liu’s latest start-up launches with $25 million to discover small molecules against non-catalytic, non-allosteric sites that influence substrate docking.

Exo debuted Wednesday with $25 million in series A funding to broaden